DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic solutions for eye diseases. It develops TeaRx Dry Eye, a CE-IVD approved test based on the TeaRx platform intended for the identification and monitoring of Dry Eye Syndrome (TeaR DES); TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis; and TeaRx Tear Collector, a proprietary microfluidic tear collector that allows non-invasive collection of 1 microliter of tear fluid and dilution in the assay buffer for downstream analytical testing. DiagnosTear Technologies Inc. was formerly known as Oceanview Technologies Inc. and changed its name to DiagnosTear Technologies Inc. The company was incorporated in 2023 and is headquartered in Rehovot, Israel.